Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 12/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765803 | 0.92 | CASP1 (0.47) | CASP1ELANEITK | |
| SCHEMBL30765492 | 0.76 | ELANE (0.49) | CASP1ELANEKDM4ESMN1; SMN2 | |
| SCHEMBL30765683 | 0.76 | TUBB4A (0.47) | CASP1ELANEKDM4ESMN1; SMN2 | |
| SCHEMBL30765459 | 0.75 | TP53 (0.45) | KDM4EALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL30765976 | 0.74 | CASP1 (0.47) | CASP1ELANECYP2C9CYP2C19 | |
| SCHEMBL30765794 | 0.74 | HDAC1 (0.46) | CASP1ELANEKDM4EALDH1A1HSD17B10 | |
| SCHEMBL30765866 | 0.74 | HDAC2 (0.51) | CASP1ELANEKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30765989 | 0.72 | KDM4E (0.51) | ELANEKDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL6245424 | 0.72 | ELANE (0.49) | CASP1ELANEKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5728202 | 0.71 | ELANE (0.54) | CASP1ELANEKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |